B. Metzler seel. Sohn & Co. AG Grows Stake in MetLife, Inc. $MET

B. Metzler seel. Sohn & Co. AG increased its holdings in MetLife, Inc. (NYSE:MET) by 39.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 63,296 shares of the financial services provider’s stock after buying an additional 18,042 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in MetLife were worth $5,214,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in MetLife during the second quarter worth about $756,104,000. Vanguard Group Inc. raised its holdings in shares of MetLife by 13.3% in the 3rd quarter. Vanguard Group Inc. now owns 64,749,521 shares of the financial services provider’s stock valued at $5,333,418,000 after acquiring an additional 7,578,199 shares in the last quarter. ABN AMRO Bank N.V. bought a new stake in shares of MetLife during the 2nd quarter valued at about $178,669,000. Amundi boosted its position in shares of MetLife by 40.2% during the 2nd quarter. Amundi now owns 4,507,362 shares of the financial services provider’s stock valued at $361,265,000 after acquiring an additional 1,292,107 shares during the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of MetLife by 173.4% during the third quarter. First Trust Advisors LP now owns 1,641,253 shares of the financial services provider’s stock worth $135,190,000 after purchasing an additional 1,040,894 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Analysts Set New Price Targets

MET has been the topic of a number of recent analyst reports. Morgan Stanley lowered their target price on shares of MetLife from $101.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Mizuho set a $100.00 price target on shares of MetLife in a research note on Thursday, February 12th. Keefe, Bruyette & Woods lowered their price objective on shares of MetLife from $92.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 11th. UBS Group lifted their price objective on shares of MetLife from $94.00 to $98.00 and gave the stock a “buy” rating in a report on Thursday, February 5th. Finally, Weiss Ratings upgraded shares of MetLife from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, February 20th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, MetLife currently has a consensus rating of “Buy” and an average price target of $94.18.

Key Stories Impacting MetLife

Here are the key news stories impacting MetLife this week:

• Positive Sentiment: MetLife confirmed its previously announced Q1 2026 dividend on its Series A floating-rate preferred shares, $0.31501229 per share, signaling consistency in capital returns for preferred holders and helping support yield-sensitive investors. Article Title
• Positive Sentiment: MetLife and partner Crow Holdings completed the sale/trade of 210 multifamily units in Tampa — an example of active portfolio management that can free capital or crystallize gains from real-estate holdings. Article Title
• Neutral Sentiment: MetLife GCC leased ~75,000 sq ft in Noida’s Oxygen Business Park — a regional expansion/lease that speaks to business presence in India but is unlikely to move the stock materially in the near term. Article Title
• Neutral Sentiment: High-profile events at MetLife Stadium (temporary renaming/World Cup hosting coverage, ticket guides) increase brand visibility and venue revenue potential, but these items are peripheral to core insurance fundamentals. Article Title
• Neutral Sentiment: A recent piece comparing MetLife’s stock performance to peers provides context for relative valuation and momentum; useful for investors but not a direct catalyst. Article Title
• Negative Sentiment: Morgan Stanley published a pessimistic forecast for MET, which likely contributed to selling pressure and the intraday decline — analyst downgrades/price-target cuts are common drivers of short-term stock weakness. Article Title

MetLife Stock Performance

NYSE:MET opened at $71.83 on Monday. The company has a quick ratio of 0.20, a current ratio of 0.20 and a debt-to-equity ratio of 0.52. The firm’s fifty day simple moving average is $77.20 and its 200 day simple moving average is $78.72. The stock has a market cap of $46.84 billion, a P/E ratio of 15.28, a price-to-earnings-growth ratio of 0.66 and a beta of 0.76. MetLife, Inc. has a twelve month low of $65.21 and a twelve month high of $85.00.

MetLife (NYSE:MET) last issued its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.49 EPS for the quarter, topping the consensus estimate of $2.34 by $0.15. MetLife had a net margin of 4.38% and a return on equity of 21.81%. The business had revenue of $52.44 billion during the quarter, compared to analyst estimates of $31.43 billion. During the same period in the prior year, the business earned $2.08 EPS. The company’s revenue for the quarter was up 27.6% on a year-over-year basis. As a group, research analysts predict that MetLife, Inc. will post 9.65 EPS for the current year.

MetLife Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 3rd will be paid a $0.5675 dividend. This represents a $2.27 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Tuesday, February 3rd. MetLife’s dividend payout ratio is presently 48.30%.

About MetLife

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.